Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Sep 19;14(1):21854.
doi: 10.1038/s41598-024-72423-x.

Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study

Toshifumi Yamaguchi  1 , Koshi Kumagai  2 , Shusuke Yagi  2 , Takashi Nomura  3 , Kengo Nagashima  4 , Masaya Watanabe  5 , Rie Makuuchi  6 , Kentaro Kawakami  7 , Tomohiro Matsushima  8 , Shigenori Kadowaki  9 , Shusuke Haruta  10 , Haruhiko Cho  11 , Naoki Kakihara  12 , Shinya Otsuka  13 , Takanobu Yamada  14 , Yoshiro Imai  15 , Narikazu Boku  16
Affiliations
Multicenter Study

Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study

Toshifumi Yamaguchi et al. Sci Rep. .

Abstract

This study aimed to survey the efficacy of chemotherapy regimens in the real world setting and explore the most promising regimen for patients experiencing early recurrence for gastric cancer. We retrospectively reviewed the clinical course of 207 patients with gastric cancer, who developed early recurrence during or within 6 months after completing S-1 adjuvant therapy at 19 Japanese institutions between 2012 and 2016. The treatment regimens after recurrence were fluoropyrimidines plus platinum-based regimens (FP) in 91 (44%) patients, paclitaxel-based regimens (PTX) in 102 (49%), and irinotecan-based regimens (IRI) in 14 (7%). The overall response and disease control rates were 28.7% and 54.1%. Median progression-free survival (PFS) and overall survival (OS) were 5.1 and 12.9 months, respectively. In the FP, PTX, and IRI regimens, the median PFS and OS were 5.9, 4.1, 4.1 months and 12.8, 12.9, and 11.8 months, respectively. The combination of PTX and ramucirumab showed survival comparable to capecitabine plus platinum. Multivariate analyses for OS showed that recurrence during adjuvant chemotherapy and undifferentiated histological type were independent poor prognostic factors. Although the prognosis of patients with early recurrence even with adjuvant S-1 was poor, PTX plus ramucirumab therapy could be a potential treatment option.

Keywords: Early relapse; Gastric cancer; Paclitaxel; Ramucirumab; S-1.

PubMed Disclaimer

Conflict of interest statement

Dr. Kengo Nagashima reports consulting fees from SENJU Pharmaceutical Co., Ltd, Toray Industries, Inc., and Kowa Company, Ltd, outside the submitted work. Dr. Takanobu Yamada reports personal fees from Taiho, Ono pharmaceutical, Bristol Squib Mayers, and Johnson and Johnson, outside the submitted work. Dr. Haruhiko Cho reports personal fees from Yakult Honsha, outside the submitted work. Dr. Shigenori Kadowaki reports personal fees from MSD, Merck KgaA, Eli Lilly, Bayer, Daiichi Sankyo, Eisai, Taiho, Ono pharmaceutical, Bristol Squib Mayers, and Chugai Pharmaceutical, outside the submitted work. Dr. Narikazu Boku reports personal fees from Taiho and Ono, Eli Lilly, Taiho, Daiichi Sankyo, and Bristol-Myers Squibb, outside the submitted work. All remaining authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
Consort diagram.
Fig. 2
Fig. 2
(a,b) Kaplan–Meier analysis of overall survival and relapse-free survival.
Fig. 3
Fig. 3
(a,b) Kaplan–Meier analysis of overall survival and relapse-free survival in the treatment groups.
Fig. 4
Fig. 4
(a) Internal comparison of the S-1 plus cisplatin and capecitabine plus cisplatin groups; Kaplan–Meier analysis of overall survival. (b) Internal comparison of the taxane-alone and taxane plus ramucirumab groups; Kaplan–Meier analysis of overall survival.
See this image and copyright information in PMC

References

    1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021). - PubMed
    1. Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med.357, 1810–1820 (2007). - PubMed
    1. Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol.29, 4387–4393 (2011). - PubMed
    1. Yoshida, K. et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J. Clin. Oncol.37, 1296–1304 (2019). - PMC - PubMed
    1. Kodera, Y. et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: A final report of the JACCRO GC-07 study. Gastric Cancer.26, 1063–1068 (2023). - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources